MONTREAL, June 18, 2024 /CNW/ - Valeo Pharma Inc. (TSX:VPH.TO) (OTC-BB:VPHIF) (FSE:VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that Mr. Al Moghaddam has been appointed to the newly created role of Chief Development Officer ("CDO") and consequently he is stepping down from the Company's Board of Directors.
Read more at newswire.caVALEO PHARMA ANNOUNCES SENIOR EXECUTIVE APPOINTMENT AND BOARD OF DIRECTORS CHANGE
Newswire.ca - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Intel%20Corp_%20logo%20on%20mobile%20phone-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
/An%20image%20of%20a%20Tesla%20humanoid%20robot%20in%20front%20of%20the%20company%20logo%20Around%20the%20World%20Photos%20via%20Shutterstock.jpg)
/Alphabet%20(Google)%20Image%20by%20Markus%20Mainka%20via%20Shutterstock.jpg)
/Nvidia%20logo%20by%20Konstantin%20Savusia%20via%20Shutterstock.jpg)
/Micron%20Technology%20Inc_%20logo%20on%20building-by%20vzphotos%20vis%20iStock.jpg)